jens juul holst glp-1 Dr. on GLP-1’s Life-Changing Impact on Metabolic Health Prof. Jens Juul Holst from

A systematic review and meta-analysis published in eClinicalMedicine found that discontinuing GLP-1 receptor agonist treatment led to an average weight regain of 5.63 kg and 5.81% of body weight across all patients studied

Some attempt to use large medical syringes for peptide injections

Jens Juul Holst Open Q&A Networking and informal discussion

They have emerged as key therapeutic targets in diabetes and obesity research, inspiring the development of dual and triple receptor agonists that synergistically enhance glycemic control, promote weight loss, and improve overall metabolic health [3]

Unclear Long-Term Outcomes: While we understand the impact of the drug taken at therapeutic doses, we do not know what impact microdosing tirzepatide might have on weight trajectories, cardiometabolic health, adherence or psychological outcomes